Estrogen receptor-a (ERa) is a central transcription factor that regulates mammary gland physiology and a key driver in breast cancer. In the present study, we aimed to identify novel modulators of ERa-mediated transcriptional regulation via a custom-built siRNA library screen. This screen was directed against a variety of coregulators, transcription modifiers, signaling molecules and DNA damage response proteins. By utilizing a microscopy-based, multi-end point, estrogen responsive biosensor cell line platform, the primary screen identified a wide range of factors that altered ERa protein levels, chromatin remodeling and mRNA output. We then focused on UBR5, a ubiquitin ligase and known oncogene that modulates ERa protein levels and transcriptional output. Finally, we demonstrated that UBR5 also affects endogenous ERa target genes and E2-mediated cell proliferation in breast cancer cells. In conclusion, our multi-end point RNAi screen identified novel modulators of ERa levels and activity, and provided a robust systems level view of factors involved in mechanisms of nuclear receptor action and pathophysiology. Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ERa protein levels and transcriptional activity.
INTRODUCTION
Estrogen receptor-a (ERa) is expressed in 70% of breast cancers, 1, 2 where it modulates several tumorigenic processes through its transcription factor activity. 3 Upon ligand binding, ERa dimerizes and binds to estrogen response elements throughout the genome recruiting histone modifying enzymes and coregulators that change chromatin structure allowing for transcriptional regulation. ERa induction of oncogenes, such as c-Myc, drives cell proliferation and tumorigenesis. 4 Therapeutics that target ERa activation, either through antagonism or degradation, 5 are the main defense against breast cancer. However, these therapies are only effective in B70% of cases (ER þ ), of which B40% develop resistance over time. 5, 6 One additional way to target ERa would be to decrease the ERa protein level through inhibition of upstream factors that control mRNA production and/or protein stability; or to restore ERa protein in ER À tumors, which could then be targeted with anti-ERa therapies.
While ERa function has many important links to pathophysiological conditions, the proteins that regulate ERa levels remain understudied. ERa mRNA is differentially regulated in various tissues/cell types: by FOXA1 in breast tissue, 7 the leptin pathway in chondrocytes, 8 ERb in uterine stromal cells and ERa autoregulation in MCF-7 breast cancer cells. 9 At the protein level, ERa turnover through proteasomal degradation via E6-AP ubiquitylation, 10 or the Skp, Cullin, F-box complex, 11 has been shown to be necessary for transactivation, while turnover through STUB1 controls its steady-state levels. 12 High throughput screening to define modulators of ERa levels and other mechanistic steps in disparate biochemical or cell-based assays can be useful for identifying novel therapeutic targets and diagnostic/prognostic avenues. Previous RNAi screens focused upon defining signaling pathways that affect ER-mediated transcription, 13 estrogenindependent growth 14 or tamoxifen resistance, 15 but have not yet carefully examined proteins that regulate ERa levels, especially in single cell-based assays. Determining which factors modulate ERa protein levels, without changing its mRNA, could have direct implications in a subset of breast tumors that have been shown to express ERa mRNA, but not protein, possibly due to a hyperactivation of the c-Src pathway.
We have previously described an estrogen receptor biosensor cell line (GFP-ERa: PRL-HeLa, hereafter referred to as PRL array cells) 16 that has been utilized to study a variety of mechanistic aspects of ERa-mediated transcription: ligands that cause ERa activation, 17, 18 functions of ERa domains, 19 and ERa interplay with other transcription factors on chromatin. 20 It is important to note that virtually all RNAi screens, including those referenced above, have been based upon single end point assays. In contrast, the PRL array system allows us to further our analysis of ERa-mediated transcriptional regulation since we can measure, simultaneously, several mechanistically relevant end points (ERa protein levels and nuclear translocation, DNA binding, chromatin remodeling and reporter gene transcriptional output). This approach is possible due to our ability to perform high throughput microscopy coupled with automated image analysis (for example, high content analysis/high content screening). Utilizing a custom designed RNAi library containing 281 selected transcriptional modulators and coregulators identified by the Nuclear Receptor Signaling Atlas (www.nursa.org; R Lanz), we interrogated the effects of their knockdown on 17-b estradiol (E2)-activated ERa nuclear levels, ERa SRC-3 and RNA polymerase II recruitment to the PRL array, chromatin remodeling and transcriptional output.
The success of the primary screen was confirmed by the identification of a series of known ERa coregulators, including PPARGC1A (PGC1a 21 ) and MED1. 22 We further chose to validate two hits that were not previously known to interplay with ERa, UBR5 and Supt5H, which we found to oppositely modulate ERa protein levels, chromatin remodeling and transcriptional activation. We then further focused upon UBR5 and showed that knockdown and overexpression oppositely modulate ERa levels and activity in MCF-7 breast cancer cells, in terms of cell proliferation and target gene regulation. The comprehensive and mechanistic data presented in this novel high content analysis-based study advances the knowledge of ERa protein level regulation and, additionally, provides a systems biology analysis of ERa transcription activation that includes identification of a new, prognostically relevant, target protein important in ERa-positive cancers.
RESULTS

A custom RNAi screen of selected coregulators identifies modulators of ERa protein level, chromatin remodeling and transcriptional output
To define novel factors that affect various stages of ERa-mediated transcription regulation, we utilized the previously characterized PRL-HeLa array cell line stably expressing GFP-ERa (PRL array, described thoroughly in Sharp et al. 16 ). Briefly, we engineered HeLa cells with a stably integrated B100 Â repeat of the estrogen responsive prolactin enhancer/promoter regulatory unit controlling a dsRED2 reporter gene, and also stably expressing GFP-ERa. This model cell line allows visualization and quantitation of multiple mechanisms linked to ERa transcription regulation. For example, the array area measurement is used as an indicator of chromatin remodeling, as agonists induce larger arrays than antagonists. The ERa nuclear and array intensities are a measure of total ERa protein in the nucleus and loaded on the array, respectively, providing a measure of how knockdowns will affect total levels of ERa and the ability of ERa to bind the response elements within the array. We also utilized the RNA FISH array intensity measure to quantify reporter gene mRNA output from the transcriptional array.
To perform the screen, PRL array cells were reverse transfected for 72 h with a custom library of siRNA pools against 281 putative transcription modulators (for full list of targeted proteins, see Supplementary Table 1 ). Each siRNA pool (consisting of three separate siRNAs to each target) transfection was performed in quadruplicate wells of a 384 multiwell plate, for 72 h, and the cells were then treated with 10 nM E2 for 30 min (Figure 1a ), then processed for dsRED2 mRNA FISH (Stellaris, Biosearch Technologies, Novato, CA, USA). Array measurements were replicated three times, while the mRNA FISH experiment was performed once, but was then repeated for the identified hits. The cells were imaged on either an IC-200 (Vala Sciences, San Diego, CA, USA) or an In Cell 6000 (GE Healthcare, Issaquah, WA, USA) high throughput microscope; subsequently, data were analyzed utilizing customized workflows developed on a PipelinePilot (Accelrys, San Diego, CA, USA) image analysis software platform. 17 Standard measurements included ERa nuclear fluorescence intensity, PRL array fluorescence intensity and area, total dsRED2 mRNA FISH signal at the array (total FISH Array intensity) and cell number (Figure 1b , see Materials and methods). As expected, utilizing POLR2A siRNA as a control for knockdown efficiency and toxicity (for example, loss of POLR2A leads to cell death 23 ), we saw a large decrease in cell number when compared with the non-targeting control siRNA ( Figure 1c ). The effect of POLR2A siRNA was confirmed across all the experimental plates, with an average Z 0score of 0.615, suggesting excellent assay quality in terms of siRNA knockdown efficiency and plate-to-plate variation (Figure 1d ). To remove the possibility of cell toxicity interfering with bona fide coregulator action, we excluded from further analysis all siRNAs that caused an 430% decrease (Z-score of À 6 compared with the mean of the control siRNA) in cell number compared with control siRNA in at least two of the assays (Figure 1e , dotted line). The full list of toxic siRNAs is presented in Supplementary Table 2. A positive 'hit' for each measured output was defined as an siRNA that caused Z-score ± 2 away from the mean of the nontargeting siRNA control (Figures 2a-c) . In this primary screen, we simultaneously evaluated ERa nuclear intensity, ERa array intensity, array area and dsRED2 mRNA FISH intensity at the array as mechanistic end points, with cell number serving for a measure of toxicity. Several general observations were readily apparent. First, utilizing Pearson's correlation coefficient, we observed a significant correlation (r ¼ 0.88) between the siRNA hits affecting ERa nuclear intensity and ERa array intensity (Supplementary Figure 1A ), suggesting that none of the siRNAs in this library have the ability to specifically block ERa DNA binding to the PRL array. Figure 2a shows all siRNAs and their effects on ERa nuclear intensity with the purple box signifying a Z-score of ± 1 from the mean of the control and the pink box being up to Z-score ±2 away. Indicated in the figure are the names of siRNAs having the largest effect on each of the selected features. There were six siRNAs affecting ERa nuclear intensity (three reduced and three increased). The ERa array intensity ( Figure 2b ) was influenced by 21 siRNAs (16 reduced and 5 increased). The array area measurement, which is linked to chromatin remodeling (Figure 2c ), was modulated by 13 factors (9 reduced and 4 increased); while total mRNA FISH intensity ( Figure 2d ) was the most affected by knockdowns (24 repressed and 5 induced). We then compared all of the hits that caused a greater than two standard deviation reduction (Figure 2e ) or increase ( Figure 2f ) in each feature. Although we observed siRNAs that affect all three categories simultaneously (for example, Supt5H), there are some siRNAs that affect only select features. For example, MED1 siRNA affected array area and mRNA FISH whereas UBR5 siRNA induced ERa and reporter gene mRNA levels, without significantly altering array area.
Several well-established ERa coregulators were present in the screen and caused changes to RNA output in the PRL system. For example, PPARGC1A (PGC1a) is a well-known coactivator of ERa in ovarian and cervical cell lines and its knockdown led to significant decreases in array area and mRNA FISH ( Figure 3 ). However, individual knockdown of other known ERa coactivators, including SRC-1, SRC-2 and SRC-3, did not pass the filter of Z-score ±2 applied to the data set. Individual SRC knockdowns did have quantifiable effects (B10-20% reduction) on ER nuclear intensity, array area and RNA FISH, with SRC-1 causing the greatest loss of reporter gene mRNA levels (35% reduction). The lack of maximal effects of the p160 coactivators in this system is not surprising, as our previous manuscript has shown compensation between at least SRC-2 and SRC-3 in regards to recruiting other TFs and serine-5 phosphorylation of RNA polymerase II at the PRL array locus. 20 Compensation has also been reported for gene-specific regulation of ERa targets by SRC-1, SRC-2 and SRC-3. 24 This is also not surprising data as it has been suggested previously that the regulation of prolactin by ERa is mainly mediated by SRC-1 in pituitary cells. 25, 26 An additional interesting observation from the screen was the extensive and factor-specific effect of knockdown of single components of the mediator complex. Mediator has been shown to have central roles in nuclear receptor-mediated transcriptional regulation especially through direct association between nuclear receptor and specific subunits, including MED1, 22,27 THRAP1 (MED13), THRAP4 (MED24), THRAP5 (MED16) and THRAP6 (MED30). The mediator complex is viewed as a four module scaffold composed of head, middle, tail and CDK substructures. 28, 29 The results of mediator knockdowns are displayed in Supplementary Figure 2A , with MED1 (middle), THRAP1 (kinase), THRAP5 (tail) and THRAP6 (middle) all having varying effects on all the features measured while THRAP4 (middle) had no effect. MED1, THRAP1 and THRAP6 knockdown all caused a decrease in ERa nuclear intensity, array area and RNA FISH; whereas THRAP5 knockdown caused an increase in all three features, indicating differential regulation by members of the mediator complex. Further, rather than the usual approach of running disparate single point assays in parallel (or sequentially), the simultaneous multiplexing performed here provides a more integrated data set that offers a systems level view of ERa functions.
Analysis of factors that affect RNA FISH, RNA Polymerase II phosphorylation and/or SRC-3 recruitment To delve deeper into the mechanism of action of hits from the primary screen that affected E2-stimulated mRNA FISH, we performed additional knockdown experiments in the PRL array cells measuring effects upon array recruitment of RNA Polymerase II (Pol II) that was phosphorylated at either serine-5 (S5P) or serine-2 (S2P), or SRC-3 ( Figure 3 ). The activating posttranslational modifications on the CTD of Pol II are known for representing transcription initiation (S5P 30 ) and transcription elongation (S2P 31 ), while SRC-3 is a well-studied ERa coactivator that is recruited to many ERa enhancers including the PRL array. 20, 32 For a more complete picture of the mechanism of action of the hits from the primary screen, we combined results from these additional experiments with the features already described in Figure 2 . We employed unsupervised clustering using Z-score from the mean for each feature as a measure. The majority of hits affecting mRNA FISH output also showed an effect on S5P or S2P, with only select siRNAs (transferrin, MED1 and ST13) affecting SRC-3 intensity at the array. This analysis allowed us to see different actions of the primary hits with regard to how they affected transcription. For example, UBR5 siRNA increased ERa levels, array area, mRNA FISH intensity, SRC-3 recruitment and transcription elongation (S2P), whereas transferrin affected ERa levels, array area, mRNA FISH intensity, but specifically increased transcription initiation (S5P), and not elongation (S2P) or SRC-3 recruitment. We also observed a similar difference in the repressive hits where Supt5H reduces all features except S2P, with the knockdown of THRAP1 reducing all features except S5P and SRC-3. A few siRNAs reduced all features including ST13 (an HSP70/HSP90 adapter protein 33 ) and C17ORF31 (a telomere-associated protein 34 ) suggesting that while the overall end point result is similar, the mechanism leading to the change is different (for example, decreased ERa levels vs reduced chromatin remodeling vs change to Pol II phosphorylation).
Validation of UBR5 and Supt5H as modifiers of ERa protein levels
We chose to further validate and explore two hits from the primary screen, UBR5 and Supt5H, which showed opposite effects on ERa levels and mRNA FISH output. Supt5H is a transcription initiation factor component of the DRB sensitivity-inducing factor complex and has a role in transcription initiation. 35 UBR5, on the other hand, is an E3 ubiquitin ligase 36 that has roles in cell cycle and DNA damage response. It has been shown to suppress ubiquitinylation of histones near damaged DNA 37 and is a known coactivator of the progesterone receptor. 38 As a first validation step we used different sets of siRNAs in the PRL array cells, which also led to a loss of ERa nuclear intensity (images in Supplementary Figure 1C) , array area and mRNA FISH intensity for Supt5H (Figure 4a ), and an increase in ERa nuclear intensity, array area and mRNA FISH intensity for UBR5 ( Figure 4b ). We also Figure 2 . Identification of hits from the primary screen. All siRNAs are charted against their changes in ERa nuclear intensity (a), ERa array intensity (b), array area (c) and total RNA FISH intensity (d), and normalized to non-targeting siRNA, with the largest inducer and repressor being labeled. The purple box represents all siRNAs with at most a Z-score of ± 1 from the control, the pink box represents all hits between 1 and 2 Z-scores from the control. Any siRNA falling outside both boxes has a Z-score of ± 2 or greater from the control. (e, f ) Venn diagrams representing the overlap between all primary hits affecting negatively (e) or positively (f ) ERa nuclear intensity, ERa array intensity, array area or total RNA FISH.
found these changes (ERa intensity increases with UBR5 knockdown and ERa intensity decreases with Supt5H knockdown) to occur regardless of ligand ( Supplementary Figures 2A and B ; E2, 4hydroxytamoxifen (Tam), fulvestrant (Ful)).
We next wanted to determine whether the observed effects were specific to ERa. We performed siRNA knockdown of Supt5H (Figure 4c ) or UBR5 (Figure 4d ) in the PRL array cells and then immunolabeled for glucocorticoid receptor (GR) and SRC-3. Following knockdown of Supt5H or UBR5, we saw no significant gain or loss of either of these proteins, suggesting a specific effect of these proteins on ERa. The knockdown efficiency, as measured by IF, approximates 65% for Supt5H ( Figure 4e ) and 45% for UBR5 ( Figure 4f ). By quantifying these changes on a single cell basis, we can record a continuum of analysis based on the knockdown efficiency; and by doing so we observed a marked shift in the population between control siRNA vs Supt5H (Supplementary Figure 2C ) or UBR5 (Supplementary Figure 2D ) that is followed by changes in the ERa protein levels. We also confirmed knockdown of UBR5 and Supt5H in PRL array cells via western blotting (Figure 4g ). Collectively, this type of analysis and resultant data suggest a specific role for both Supt5H and UBR5 in the regulation of ERa protein levels.
Next, we also wanted to determine whether these proteins were components of the ERa transcription complex in the PRL array cell line. To do this, we treated PRL array cells with 10 nM E2 for 30 min and then immunolabeled with antibodies against Supt5H (Supplementary Figure 2E ) or UBR5 (Supplementary Figure 2F ). Interestingly, neither Supt5H nor UBR5 localized to the PRL array with ERa suggesting that their control over ERa levels does not occur at the PRL reporter gene locus.
UBR5 knockdown modulates ERa, but not GR or SRC-3 levels in MCF-7 cells
Due to the importance of ubiquitin ligases in ERa-mediated transcription and protein level modulation, we performed additional follow-up studies with UBR5. As shown in Figure 4g , immunoblotting showed that a loss of UBR5 led to an increase in ERa levels. By design, ERa expression in PRL-HeLa cells is driven by a CMV containing promoter; further, the protein is GFP tagged. As such, we sought to determine whether UBR5 knockdown would also affect endogenously expressed ERa. We therefore performed UBR5 siRNA knockdown in MCF-7 breast cancer cells, and then immunolabeled them with antibodies to ERa, GR or SRC-3. Similar to results from the PRL array cell line, MCF-7 cells also showed an increase in ERa intensity with UBR5 knockdown, but no changes in GR or SRC-3 intensity (Figure 5a ). We then validated this result by western blotting (Figure 5b ). We further validated the effect of UBR5 knockdown on ERa in T47D cells (Supplementary Figure 2G) . Collectively, these data confirmed our RNAi screening results in the PRL-HeLa cells and suggest that the changes in ERa level exerted by UBR5 are not dependent upon cell type, CMV promoter or GFP tag.
Next, in order to determine whether this new ERa modulator has translational relevance, we utilized the cBio Cancer Genomics Portal, 39 which allows a user to query a specific gene, or set of genes, and determine their alterations (that is, amplifications, deletions and mutations) across a variety of cancer genomics data sets. Interestingly, we observed that alterations in the UBR5 locus occur in many breast tumors (B30%) and are a prognostic factor for a poor outlook (Supplementary Figure 3A) , especially in the luminal A subtype (Figure 5c ) compared with the other subtypes ( Supplementary Figure 3B-D) . These data were also confirmed by querying the TCGA database. 40 
UBR5 modulates ERa-induced gene expression and proliferation through its ubiquitin ligase activity
We next sought to determine whether UBR5 ubiquitin ligase activity was required for modulation of ERa levels. As such, we overexpressed Flag-tagged UBR5 or Flag-tagged UBR5 containing a C2768A point mutation that disrupts its ubiquitin ligase activity 38 in MCF-7 cells. Using immunofluorescence combined with single cell analysis, overexpression of Flag-UBR5 was shown to greatly reduce ERa protein levels (Figure 5d ), and overexpression of the inactive UBR5 mutant caused no change when compared with non-transfected cells. These results confirmed the effect of UBR5 as a negative regulator of ERa protein levels and indicated a mechanistic dependence for ubiquitin ligase activity.
After exploring the effects of UBR5 modulation of ERa protein level, we wanted to determine whether it also affected ESR1 mRNA in MCF-7. Upon UBR5 knockdown, we observed an B50% decrease in ESR1 mRNA (Figure 6a ) which is consistent with the previously reported 9 observation that ERa auto-regulates its own expression by binding to its gene locus and recruiting a Sin3A containing repressor complex. To determine whether this mechanism could occur also in this scenario, we performed chromatin immunoprecipitation of ERa after control or UBR5 siRNA transfection. As shown in Figure 6b , upon UBR5 depletion, ERa occupancy at the ESR1 locus does increase in a ligandindependent manner.
We then wanted to determine whether the increase in ERa protein upon UBR5 knockdown lead to changes in transcriptional activation of an endogenous ER target gene. We quantified the E2induced expression of GREB1 mRNA, a well-known ERa target gene, by qPCR. Knockdown of UBR5 (Figure 6c ) resulted in an increased induction of GREB1 in cells treated with 10 nM E2 without changes in the basal mRNA level, thus suggesting a possible role for UBR5 functioning as a rheostat that controls the magnitude of ERa responses.
To test whether UBR5 also impacted E2-induced cell proliferation, we performed EdU pulse labeling (B10 min), which captures cells in S phase of the cell cycle. Here, MCF-7 cells were treated with 10 nM E2 for 24 h following knockdown of UBR5. Figure 6d shows that, in control siRNA samples, B23% of cells were EdU positive; however, UBR5 knockdown resulted in an 450% increase in EdU-positive cells (B35%). These data were confirmed by monitoring the mRNA expression of Cyclin D1, another ERa target gene, which showed a marked increase in E2 stimulation with UBR5 knockdown compared with control ( Figure 6e ). This increase in proliferation upon loss of UBR5 was not recapitulated in the ERa-negative MDA-MB-231 cell line (Figure 6f ). These data provide further evidence that regulation of ERa levels by UBR5 lead to downstream effects on ERa signaling, thus providing us with new possible prognostic and therapeutic targets for ERa-mediated disease.
DISCUSSION
ERa is a key transcription factor in many physiological processes including breast and bone development. 41, 42 Alterations in ERa signaling are observed in many pathophysiological conditions including breast cancer and osteoporosis. While ERa is expressed in 70% of breast cancers, 1,2 it is a protein coregulator that aids in the modulation of transcriptional regulation and can be amplified in disease. 43, 44 It is for this reason that we set out to utilize our PRL array system, which can be used to simultaneously observe many mechanistic steps of ERa-mediated transcriptional activation, 17, 19, 45 and identify those factors that mediate ER levels and activity.
In our primary screen using a custom RNAi library containing 281 putative transcription regulators (see Supplementary Table 1) we confirmed the role for a variety of known ERa coregulators in our model system, including PPARGC1A (PGC1a) and MED1. PGC1a has been shown to coactivate ERa through the ERa hinge region. 21, [46] [47] [48] Our screen identified five other subunits of the Mediator complex, four of which showed effects in the PRL array line when knocked down. The only mediator subunit not to affect ER activity was THRAP4 (MED24), whereas MED1, THRAP1 (MED13), THRAP5 (MED16) and THRAP6 (MED30) all showed robust effects. Although mediator components are more known for their role in RNA Polymerase II recruitment, we observed that two of the mediators (MED1 and MED16) have larger effects upon array area. These data agree with a recent report suggesting that these proteins can interact with long, non-coding RNAs to affect chromatin remodeling. 49 Interestingly, while the loss of the majority of the mediator proteins caused a decrease in transcription, MED16 knockdown increased reporter activity, suggesting that its presence may actually have an overall repressive effect on transcription. Of note, MED16 repression on transcription has been reported previously on ribosomal protein mRNAs. 50 We also found a potentially interesting modulator of ERa-mediated transcription in FTH1, the cellular iron storage protein, whose knockdown led to decreased array area and dsRED2 mRNA production. These findings help confirm that our screen can identify known coregulators and, simultaneously, can also efficiently ascribe certain mechanistic details about their modus operandi.
To validate and extend the results from our RNAi screen, we chose two proteins, Supt5H and UBR5, whose reduction showed opposite effects on all ERa features; further, we then focused deeper on UBR5, an E3 ubiquitin ligase reported to play roles in cell cycle, 51 DNA damage repair pathways, 37 and known to ubiquitylate PEPCK 36 and CDK9, 52 which we identify as a novel negative prognostic factor in breast cancer. Our results are the first linking UBR5 to ERa protein regulation, although it has been shown to regulate the activity of the progesterone receptor. 38 It is known that other ubiquitin ligase family members (for example, E6AP 53 ) can ubiquitinylate ERa after Src activation leading to an increase in both protein turnover and activity upon E2 treatment. 10 It is commonly thought that this activation is through mono-ubiquitinylation of K302/303, 54 whereas polyubiquitinylation of unliganded ERa leads to degradation. 55, 56 This ubiquitinylation event is different upon fulvestrant treatment that causes ERa localization to nuclear intermediate filaments followed by ubiquitinylation and subsequent degradation. 57 Interestingly, UBR5 knockdown showed increases in ERa levels independent of ligand, providing further evidence that it can regulate steady-state levels of the protein.
The identification of UBR5 as a potential novel ubiquitin ligase for ERa is of clinical relevance since UBR5 gene is located in a region of the genome (8q22) amplified in B30% of breast cancers, 58,59 providing a possible mechanism for ERa protein-negative, ERa-mRNA-positive tumors. Furthering the results in the PRL array model, we showed a loss of UBR5 in MCF-7 resulted in an increase in ERa transcriptional activity and proliferative capabilities. We also demonstrate that increased UBR5 levels lead to a decrease in ERa protein and that this is dependent upon an active ubiquitin ligase domain in UBR5. These findings open the potential for new drug screening and therapeutic options for breast cancer subtypes linked to UBR5 expression. In conclusion, our highly multiplex and mechanism-oriented RNAi screen has provided an expanded view of known and novel factors that impinge upon ERa-mediated transcriptional regulation. Furthermore, the robustness and the translatability of the results obtained from the PRL array platform will permit us to explore additional RNAi libraries or specific small molecule inhibitors to identify novel mediators and pathways affecting ER actions. For example, ERa is well known to be under control of a variety of kinase signaling pathways but interpreting the effects of these pathways upon the ER 'complexosome' is complicated by disparate experimental approaches. Utilization of a highly multiplexed siRNA screen to the human kinome will help elucidate some of these mechanisms, while expanding the approach to a genome-wide siRNA will provide a global systems level view of proteins that can influence ERa-mediated transcription. These and other approaches are poised to define further prognostic and therapeutic targets for ERa þ diseases.
MATERIALS AND METHODS
RNAi screen, cell culture and transfections GFP-ERa:PRL-HeLa and MCF-7 cells were maintained as previously described. 20 For the RNAi screen, GFP-ERa:PRL-HeLa cells were plated in 5% stripped-dialyzed FBS, phenol red-free DMEM onto Aurora 384-well plastic bottom plates which had been seeded with Lipofectamine RNAiMax reagent (1:50 dilution) and 40 nM siRNA duplex. Cells were incubated for 72 h followed by treatment with 10 nM E2 for 30 min. The cells were then processed for antibody or mRNA FISH using a Beckman Coulter Biomek FX robot (Beckman-Coulter, Brea, CA, USA). siRNA transfection in MCF-7 cells was done as mentioned above using a custom Stealth siRNA library (a kind gift from Invitrogen, Carlsbad, CA, USA).
For immunolabeling, we followed the same protocol as in Bolt et al. 20 using anti-GR (GeneTex, Irvine, CA, USA, GTX101120), ERa (Millipore, Billerica, MA, USA, 04-820), Ser5-phospho RNA Polymerase II (ABCAM (Cambridge, MA, USA, ab5401), Ser2-phospho RNA Polymerase II (ABCAM, ab5095), Supt5H (ABCAM, ab126592), UBR5 (ABCAM, ab70311), SRC-3 (BD Transduction Labs, San Jose, CA, USA, # 611105), Alexa Fluor 647 goat anti-rabbit IgG or Alexa Fluor 647 goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA).
For mRNA FISH, cells were fixed in 4% formaldehyde in RNase-free PBS for 15 min and then permeabilized with 70% ethanol in RNAse-free water at 4 1C for 1 h. Cells were washed in 1 ml wash buffer (2 Â SSC, 10% formamide) followed by hybridization in hybridization buffer (comprises 1 g dextran sulfate, 1 ml 20 Â SCC buffer, 1 ml formamide, 8 ml nucleasefree water) with RNA probes (dsRED2 Stellaris probes; Biosearch Technologies Inc) for 4 h at 37 1C followed by one wash in wash buffer for 30 min at 37 1C and then DAPI staining for 10 min at 37 1C. Cells were held and imaged in 2 Â SCC buffer. GFP-UBR5, pCMV-Tag2B-UBR5 and pCMV-Tag2B-UBR5 C2768A have been characterized previously. 38 
Imaging and quantification
Automated imaging was carried out using an IC-200 image cytometer (Vala Sciences) or an In Cell 6000 (GE Healthcare). In each instance, image acquisition was performed with a Nikon S Fluor Â 40/0.90NA objective. Z-stacks were imaged at 0.3 mm intervals at 1 Â 1 binning. Nuclear, array segmentation and automated image analyses were performed using PipelinePilot image analysis software as previously described. 17 
Western blotting
Cell lysates were obtained from scraping cells into ice-cold NP-40 lysis buffer. Lysates were then combined with LDS Sample Buffer (Novex, Carlsbad, CA, USA) and boiled for 5 min. Samples were then loaded onto 12-well 8-12% acrylamide gels and run at 200 V at 4 1C for 90 min. Gels were then transferred onto Immobilon transfer membranes at 4 1C for 2 h at 80 V. Non-specific antibody binding was blocked by treating membranes with 5% milk in TBS-T.
Quantitative RT-PCR
Total RNA was isolated using Trizol (Life Technologies, Carlsbad, CA, USA) as per the manufacturer's instructions. RT and qPCR were performed as previously described. 20 Reactions were carried out in an Applied Biosystems StepOne Plus (Carlsbad, CA, USA). The fold change in expression was calculated using the DD Ct comparative threshold cycle method with the ribosomal protein 36B4 mRNA as an internal control.
Statistical analysis and software
Data presented were acquired from a minimum of three independent experiments performed on different days using similar cell passage numbers. P-value was determined using Student's t-test for single comparisons or one-way ANOVA for independent samples and a Tukey HSD post hoc test for comparisons across multiple samples.
The data for the heat map in Figure 3 were generated using Cluster 3.0 utilizing City Block Distance clustering with a centroid linkage method 60 and then visualized using Java Treeview. 61 The Venn diagrams in Figure 2 were generated using the Venny software (Oliveros JC 2007, http:// bioinfogp.cnb.csic.es/tools/venny/index.html).
